Mastering the Complex Targeted Therapy for Non-small Cell Lung Cancer

Siddhartha Devarakonda; Ramaswamy Govindan; Daniel Morgensztern

doi:10.1016/j.ccell.2020.07.011

Mastering the Complex Targeted Therapy for Non-small Cell Lung Cancer

Siddhartha Devarakonda, Ramaswamy Govindan, Daniel Morgensztern

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

In a recent Nature article, Middleton et al. report the National Lung Matrix trial results where patients with previously treated non-small cell lung cancer (NSCLC) are assigned to personalized therapy based on the results of a 28-gene next-generation sequencing panel test.

Original language	English
Pages (from-to)	320-322
Number of pages	3
Journal	Cancer Cell
Volume	38
Issue number	3
DOIs	https://doi.org/10.1016/j.ccell.2020.07.011
State	Published - Sep 14 2020

Access to Document

10.1016/j.ccell.2020.07.011

Cite this

@article{05dd9a6156bd458eb72e430fabc946a7,

title = "Mastering the Complex Targeted Therapy for Non-small Cell Lung Cancer",

abstract = "In a recent Nature article, Middleton et al. report the National Lung Matrix trial results where patients with previously treated non-small cell lung cancer (NSCLC) are assigned to personalized therapy based on the results of a 28-gene next-generation sequencing panel test.",

author = "Siddhartha Devarakonda and Ramaswamy Govindan and Daniel Morgensztern",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2020",

month = sep,

day = "14",

doi = "10.1016/j.ccell.2020.07.011",

language = "English",

volume = "38",

pages = "320--322",

journal = "Cancer Cell",

issn = "1535-6108",

number = "3",

}

TY - JOUR

T1 - Mastering the Complex Targeted Therapy for Non-small Cell Lung Cancer

AU - Devarakonda, Siddhartha

AU - Govindan, Ramaswamy

AU - Morgensztern, Daniel

PY - 2020/9/14

Y1 - 2020/9/14

N2 - In a recent Nature article, Middleton et al. report the National Lung Matrix trial results where patients with previously treated non-small cell lung cancer (NSCLC) are assigned to personalized therapy based on the results of a 28-gene next-generation sequencing panel test.

AB - In a recent Nature article, Middleton et al. report the National Lung Matrix trial results where patients with previously treated non-small cell lung cancer (NSCLC) are assigned to personalized therapy based on the results of a 28-gene next-generation sequencing panel test.

UR - http://www.scopus.com/inward/record.url?scp=85090965302&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2020.07.011

DO - 10.1016/j.ccell.2020.07.011

M3 - Article

C2 - 32857949

AN - SCOPUS:85090965302

VL - 38

SP - 320

EP - 322

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 3

ER -

Mastering the Complex Targeted Therapy for Non-small Cell Lung Cancer

Abstract

Access to Document

Other files and links

Fingerprint

Cite this